Get the Stockscreener App
20.86
2.81%
0.57
After Hours:
20.72
-0.14
-0.67%
Kalvista Pharmaceuticals Inc stock is traded at $20.86, with a volume of 889.26K.
It is up +2.81% in the last 24 hours and up +23.14% over the past month.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
See More
Previous Close:
$20.29
Open:
$20.33
24h Volume:
889.26K
Relative Volume:
0.86
Market Cap:
$1.07B
Revenue:
$75.04M
Net Income/Loss:
$-167.18M
P/E Ratio:
-6.5255
EPS:
-3.1967
Net Cash Flow:
$-168.39M
1W Performance:
+8.25%
1M Performance:
+23.14%
6M Performance:
+74.71%
1Y Performance:
+73.54%
1-Day Range:
$20.02
$20.91
1-Week Range:
$19.14
$20.91
52-Week Range:
$9.83
$21.30
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Name
Kalvista Pharmaceuticals Inc
Sector
Industry
Phone
(857) 999-0075
Address
200 CROSSING BOULEVARD, FRAMINGHAM, MA
Compare KALV vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
20.86 | 1.04B | 75.04M | -167.18M | -168.39M | -3.1967 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Reiterated | Needham | Buy |
| Jan-06-26 | Reiterated | Needham | Buy |
| Jan-31-25 | Initiated | JMP Securities | Mkt Outperform |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Dec-18-24 | Initiated | BofA Securities | Buy |
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Jul-29-19 | Initiated | SVB Leerink | Outperform |
| Mar-20-19 | Initiated | Needham | Buy |
| Oct-30-18 | Initiated | Jefferies | Buy |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-31-17 | Initiated | BTIG Research | Buy |
View All
Kalvista Pharmaceuticals Inc Stock (KALV) Latest News
KALV SEC FilingsKalvista Pharm 10-K, 10-Q, 8-K Forms - Stock Titan
How Investors May Respond To KalVista Pharmaceuticals (KALV) Early KONFIDENT-KID Completion And Positive EKTERLY Data - Sahm
Inflation Data: Is KalVista Pharmaceuticals Inc subject to activist investor interestDay Trade & Growth Focused Investment Plans - baoquankhu1.vn
Market Moves: Is KalVista Pharmaceuticals Inc impacted by rising ratesWeekly Investment Summary & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
KalVista Pharmaceuticals Inc (HAM:4XC1) Valuation - GuruFocus
KalVista posts $49.1 million in EKTERLY revenue during eight-month transition period - MSN
Behavioral Patterns of KALV and Institutional Flows - Stock Traders Daily
Investor Mood: Is KalVista Pharmaceuticals Inc forming higher highs and higher lows2026 AllTime Highs & Community Trade Idea Sharing Platform - baoquankhu1.vn
Merger Talk: Will KalVista Pharmaceuticals Inc face regulatory challenges2026 Price Momentum & High Accuracy Investment Signals - baoquankhu1.vn
Ekterly pill may change how families treat HAE attacks in young children - Angioedema News
Death Cross: Can KalVista Pharmaceuticals Inc expand its profit marginsShort Setup & High Accuracy Trade Alerts - baoquankhu1.vn
Breakout Zone: Can KalVista Pharmaceuticals Inc deliver consistent dividendsProduct Launch & Daily Stock Trend Watchlist - baoquankhu1.vn
KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference - joplinglobe.com
KALV PE Ratio & Valuation, Is KALV Overvalued - Intellectia AI
KalVista Pharmaceuticals: Ekterly's Launch Momentum Keeps The Bull Case Alive (KALV) - Seeking Alpha
JonesTrading Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $39 - Moomoo
Big Picture: Will KalVista Pharmaceuticals Inc face regulatory challengesMarket Performance Recap & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Wall Street Zen Downgrades KalVista Pharmaceuticals (NASDAQ:KALV) to Hold - marketbeat.com
Why KalVista Pharmaceuticals (KALV) Is Up 5.0% After Promising Pediatric EKTERLY HAE Trial Results – And What's Next - Sahm
A Look At KalVista Pharmaceuticals (KALV) Valuation After Positive KONFIDENT KID EKTERLY Trial Update - Sahm
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
KalVista Pharmaceuticals (NASDAQ:KALV) Hits New 1-Year HighShould You Buy? - MarketBeat
KALV Should I Buy - Intellectia AI
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
KalVista Pharmaceuticals (KALV) Is Up 22.4% After Early Success In Pivotal Pediatric HAE Trial - Yahoo Finance
KalVista Pharmaceuticals Stock: Positive Pediatric Trial Data Positions KALV for HAE Market Expansio - AD HOC NEWS
Hennion & Walsh Asset Management Inc. Boosts Stake in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
KalVista reports interim data on pediatric HAE treatment trial By Investing.com - Investing.com South Africa
KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference - BioSpace
(KALV) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
KalVista (KALV) Announces Positive Interim Results from KONFIDEN - GuruFocus
KalVista Announces Positive Interim Data for Pediatric HAE Treatment - National Today
KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data - The National Law Review
KalVista reports interim data on pediatric HAE treatment trial - Investing.com
HC Wainwright Has Negative Forecast for KALV FY2028 Earnings - MarketBeat
KalVista Pharmaceuticals Inc Stock Historical Valuations | HAM:4XC1 - GuruFocus
Stifel Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) Major Shareholder Sells 174,645 Shares of Stock - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Major Shareholder Venrock Healthcare Capital Par Sells 39,986 Shares of Stock - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Upgraded to Buy at Wall Street Zen - MarketBeat
Venrock healthcare sells KalVista (KALV) shares for $3.69 million - Investing.com UK
Venrock healthcare sells KalVista (KALV) shares for $3.69 million By Investing.com - Investing.com South Africa
Venrock funds trim KalVista (KALV) stake, retain 5.09M shares - stocktitan.net
KalVista Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:KALV) - MarketBeat
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), KalVista Pharmaceuticals (KALV) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Wall Street analysts think KalVista Pharmaceuticals (KALV) could surge 117.1%: Read this before placing a bet - MSN
KalVista Pharmaceuticals (NASDAQ:KALV) Sets New 12-Month High Following Analyst Upgrade - MarketBeat
KalVista Pharmaceuticals (KALV) Q4 Revenue Jump Tests Bullish Profitability Narrative - simplywall.st
H.C. Wainwright reiterates Kalvista stock Buy rating at $37 target By Investing.com - Investing.com Australia
Analysts Are Bullish on Top Healthcare Stocks: KalVista Pharmaceuticals (KALV), Achieve Life Sciences (ACHV) - The Globe and Mail
KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Up 8.7% on Analyst Upgrade - MarketBeat
Kalvista Pharmaceuticals Inc Stock (KALV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kalvista Pharmaceuticals Inc Stock (KALV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Venrock Healthcare Capital Par | 10% Owner |
Mar 26 '26 |
Sale |
18.28 |
39,986 |
730,822 |
5,089,354 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
Mar 09 '26 |
Sale |
16.08 |
6,693 |
107,633 |
451,815 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER |
Feb 23 '26 |
Sale |
15.57 |
5,354 |
83,345 |
138,983 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
Feb 23 '26 |
Sale |
15.57 |
10,034 |
156,197 |
442,883 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER |
Feb 23 '26 |
Sale |
15.57 |
4,347 |
67,669 |
226,701 |
| Sweeny Nicole | Chief Commercial Officer |
Feb 23 '26 |
Sale |
15.57 |
3,975 |
61,878 |
47,003 |
| Piekos Brian | Chief Financial Officer |
Feb 23 '26 |
Sale |
15.57 |
1,767 |
27,507 |
13,762 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
Feb 18 '26 |
Sale |
15.00 |
1,038 |
15,570 |
429,667 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER |
Feb 18 '26 |
Sale |
15.00 |
1,163 |
17,445 |
133,087 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER |
Feb 18 '26 |
Sale |
15.00 |
1,109 |
16,635 |
224,173 |
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):